Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jpn J Clin Oncol. 2020 May 5;50(5):535-542. doi: 10.1093/jjco/hyaa011.
This study was to evaluate the safety and effectiveness of carbon nanoparticles suspension in tracking lymph node metastases of colorectal cancer.
Eligible patients diagnosed with stages I-III colorectal cancer in Fudan University Shanghai Cancer Center between 1 May 2017 and 31 May 2018 fulfilling the inclusion criteria were included in this prospective randomized controlled study. All the patients were randomly allocated to two groups: the nanocarbon group and the control group. Patients' clinicopathological characteristics were compared between the nanocarbon group and the control group. For continuous variables, data were presented as mean (±SD) and differences between the two groups were compared by the Mann-Whitney U test; for categorical variables, data was presented as frequency (%) and the Pearson's chi-squared test was used to compare the differences between two groups.
All the patients' characteristics between two groups did not achieve statistical significance (P > 0.05). Patients in nanocarbon group were more likely to be associated with more lymph nodes retrieved totally compared with control group (19.84 ± 6.428 vs. 17.41 ± 7.229, P < 0.001). The number of lymph nodes retrieved in nanocarbon group were more likely to be ≥12 than that in the control group (P = 0.005).
Our study confirmed the safety of using carbon nanoparticles suspension as a tracer in colorectal cancer. More importantly, nanocarbon could significantly increase the detected number of lymph nodes in colorectal cancer, which can help improve the accuracy of lymph node staging and even improve patients' survival.
本研究旨在评估碳纳米粒子混悬液在追踪结直肠癌淋巴结转移中的安全性和有效性。
本研究为前瞻性随机对照研究,纳入 2017 年 5 月 1 日至 2018 年 5 月 31 日期间在复旦大学附属肿瘤医院经病理诊断为 I-III 期结直肠癌且符合纳入标准的患者。所有患者均随机分为纳米碳组和对照组。比较两组患者的临床病理特征。对于连续变量,数据以均数(±标准差)表示,两组间比较采用 Mann-Whitney U 检验;对于分类变量,数据以频率(%)表示,两组间比较采用 Pearson's χ2 检验。
两组患者的所有特征均无统计学意义(P>0.05)。纳米碳组患者的总检出淋巴结数较对照组更可能增加(19.84±6.428 比 17.41±7.229,P<0.001)。纳米碳组检出的淋巴结数更可能≥12 个,而对照组则不然(P=0.005)。
本研究证实了使用碳纳米粒子混悬液作为示踪剂在结直肠癌中的安全性。更为重要的是,纳米碳可以显著增加结直肠癌中检测到的淋巴结数量,这有助于提高淋巴结分期的准确性,甚至改善患者的生存。